Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors

Anti-Cancer Drugs

Volumn 15, Issue 9, 2004, Pages 849-860

  Di Nicolantonio, Federica ^a   Knight, Louise A ^a   Di Palma, Silvana ^a   Sharma, Sanjay ^a   Whitehouse, Pauline A ^a   Mercer, Stuart J ^a   Charlton, Peter A ^b   Norris, David ^b   Cree, Ian A ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

ATP; Chemosensitivity; MLN576; Ovarian cancer; P glycoprotein; Resistance; Topoisomerase; XR11576; XR5000

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; ANTINEOPLASTIC AGENT; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; PACLITAXEL; PARAFFIN; PHENAZINE DERIVATIVE; TOPOTECAN; TREOSULFAN; UNCLASSIFIED DRUG; XR 11576;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER TISSUE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG ANTAGONISM; DRUG POTENCY; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; GASTROINTESTINAL TUMOR; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PHENAZINES; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED;

EID: 8344240471     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200410000-00005     Document Type: Article

References (46)

1. Denny WA, Baguley BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Topics Med Chem 2003; 3:339-353.
2. Finlay GJ, Riou JF, Baguley BC. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 1996; 32A:708-714.
3. Riou JF, Fossé P, Nguyen CH, Larsen AK, Bissery MC, Grondard L, et al. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res 1993; 53:5987-5993.
4. Perrin D, van Hille B, Barret JM, Kruczynski A, Etiévant C, Imbert T, et al. F11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochem Pharmacol 2000; 59:807-819.
5. Stewart AJ, Mistry P, Dangerfield W, Bootle D, Baker M, Kofler B, et al. Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs 2001; 12:359-367.
6. Mistry P, Stewart AJ, Dangerfield W, Baker M, Liddle C, Bootle D, et al. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs 2002; 13:15-28.
7. Mistry P, Harris P, Dangerfield W, Kofler B, Bootle D, Stewart A, et al. XR11612, a novel dual inhibitor of topoisomerase I and II with potent antitumour activity. Clin Cancer Res 2001; 7(suppl 11): abstr 459.
8. Utsugi T, Aoyagi K, Asao T, Okazaki S, Aoyagi Y, Sano M, et al. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res 1997; 88:992-1002.
9. Byl JAW, Fortune JM, Burden JA, Nitiss JL, Utsugi T, Yamada Y. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Biochemistry 1999; 38:15573-15579.
10. Jobson A, Willmore E, Tilby M, Mistry P, Charlton P, Austin C. Characterisation of the roles of Topoisomerase I and II in the mechanism of action of novel anti-tumour agents XR11576 (MLN576) and XR5944 (MLN944). Eur J Cancer 2002; 38(suppl 7):31 (abstr 86).
11. Jobson A, Willmore E, Tilby M, Mistry P, Charlton P, Austin C. Characterization of the roles of Topoisomerase I and II in the mechanism of action of the novel anti-tumor agent XR11576 (MLN576). Proc Am Ass Cancer Res 2003; 44(1st edn):abstr 1601.
12. Yang D, Dai D, Mistry P. Structural Studies of XR5944 (MLN944) and XR11576 (MLN576) Interactions with DNA. Clin Cancer Res 2003; 9:abstr A58.
13. Cree IA, Kurbacher CM. ATP based tumour chemosensitivity testing: assisting new agent development. Anticancer Drugs 1999; 10:431-435.
14. Neale MH, Charlton PA, Cree IA. Ex vivo activity of XR5000 against solid tumours. Anticancer Drugs 2000; 11:471-478.
15. Cree IA. Chemosensitivity testing as an aid to anti-cancer drug and regimen development. Rec Results Cancer Res 2003; 161:119-125.
16. Hunter EM, Sutherland LA, Cree IA, Subedi AMC, Hartmann D, Linder D, et al. The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. Anticancer Drugs 1994; 5:171-176.
17. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
18. Norton AJ, Jordan S, Yeomans P. Brief, high temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994; 173:371-379.
19. Cree IA. Luminescence-based cell viability testing. Methods Mol Biol 1998; 102:169-177.
20. Poch G, Reiffenstein RJ, Baer HP. Quantitative estimation of potentiation and antagonism by dose ratios corrected for slopes of dose-response curves deviating from one. J Pharmacol Toxicol Methods 1995; 33:197-204.
21. Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Poch G, et al. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res 1997; 3:1527-1533.
22. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJE, Hungerford JL, et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999; 79:1487-1493.
23. Di Nicolantonio F, Neale MH, Knight LA, Lamont A, Skailes GE, Osborne RJ, et al. Use of an ATP-based chemosensitivity assay to design new combinations of high concentration doxorubicin with other drugs for recurrent ovarian cancer. Anticancer Drugs 2002; 13:625-630.
24. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Reg 1984; 22:27-55.
25. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47:331-385.
26. Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW. TCA-100 Tumor Chemosensitivity Assay: differences in sensitivity between cultured tumor cell lines and clinical studies. J Biolumin Chemilumin 1994; 9:373-378.
27. Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, et al. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs 1999; 10:437-444.
28. Whitehouse PA, Knight LA, Di Nicolantonio F, Mercer SJ, Sharma S, Cree IA. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Anticancer Drugs 2003; 14:369-375.
29. Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Di Nicolantonio F, et al. Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. Anticancer Drugs 2003; 14:397-403.
30. Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, et al. Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 1997; 79:521-527.
31. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000; 6:1415-1421.
32. Irving JA, Hall AG. Mismatch repair defects as a cause of resistance to cytotoxic drugs. Expert Rev Anticancer Ther 2001; 1:149-158.
33. Matsumoto Y, Takano H, Fojo T. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res 1997; 57:5086-5092.
34. Dingemans AMC, Witlox MA, Stallaert RALM, van der Valk P, Postmus PE, Giaccone G. Expression of DNA Topoisomerase II and Topoisomerase II genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999; 5:2048-2058.
35. Koshiyama M, Fujii H, Kinezaki M, Morita Y, Nanno H, Yoshida M. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res 2001; 21(4B):2925-2932.
36. Fleming JA, Blackman RK, Thoroddsen V, Rudolph-Owen L, Charlton P, Bulawa C. Using yeast to probe the mechanism of action of MLN944 (XR5944), a novel bis-phenazine with potent anti-tumor activity. Proc Am Ass Cancer Res 2003; 44(2nd edn):abstr 6574.
37. Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol 2001; 48:188-196.
38. Barret JM, Kruczynski A, Etievant C, Hill BT. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Cancer Chemother Pharmacol 2002; 49:479-486.
39. Jonsson E, Fridborg H, Nygren P, Larsson R. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol 1998; 54:509-514.
40. Sargent JM, Elgie AW, Williamson CJ, Hill BT. Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs 2003; 14:467-473.
41. de Jonge MJ, Sparreboom A, Verweij J. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. Cancer Treat Rev 1998; 24:205-220.
42. Kano Y, Akutsu M, Tsunoda S, Mori K, Suzuki K, Adachi KI. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol 1998; 42:91-98.
43. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996; 88:734-741.
44. Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 1998; 41:307-316.
45. Perez EA, Buckwalter CA. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother Pharmacol 1998; 41:448-452.
46. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86:1517-1524.